Investor Summary

Investor Summary

Duniya SanoStem presents an FDA-submitted CBER IND 33055 cell therapy program for ischemic stroke, with Phase IIb/III-ready clinical-development positioning, allogeneic MSC technology, manufacturing-readiness planning, and U.S., India, and UAE/Dubai expansion strategy.

Partnership Areas

• Clinical development
• Hospital networks
• Manufacturing
• Regulatory strategy
• India launch planning
• UAE / Dubai launch planning
• Financing
• Licensing
• Strategic commercialization